Developer docs
API playgroundTry for free, no card

Search company profiles

Omniox

Full company profile

uuid00034fg

Namestring
Omniox
Legal namestring
Omniox, Inc.
Websiteurl
omniox.com
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Omniox is an early-stage, venture-backed biopharmaceutical company headquartered in San Francisco, California (incorporated in Delaware) that is developing an engineered oxygen-carrier platform designed to deliver oxygen specifically to hypoxic tissues. The company's stated therapeutic thesis targets unmet medical needs in cancer, cardiovascular disease, and trauma, where tissue hypoxia contributes to treatment resistance and poor clinical outcomes; the platform is positioned to selectively oxygenate hypoxic tumors and ischemic cardiovascular tissue rather than functioning as a general blood substitute. Technology disclosure is limited to a high-level description of the oxygen-delivery architecture, with no named product candidates, no disclosed patents, no clinical trial data, and no regulatory milestones provided in available sources.

Omniox operates as a private, R&D-only organization with 1-10 employees, no commercial revenue, and no pricing or distribution model yet established. Its business model to date has been capital-formation-driven: cumulative disclosed equity and debt raises total roughly $28-31 million across rounds dated 2013, 2014 (from Casdin Capital and Wellcome Trust, among others), 2016 (~$28M SEC Form D), 2018, 2023, and 2024 (~$3.36M SEC Form D), with named institutional backers including Casdin Capital, Wellcome Trust, Samsara BioCapital, Acadia Woods Partners, Baker Brothers Advisors, EcoR1 Capital, Wavemaker 360, and Plug and Play. The intended end-customers are healthcare providers and patients in oncology and cardiovascular indications, but the company remains pre-commercial with no active distribution or marketing channels.

Governance is led by CEO Jonathan Winger, with founder Stephen Cary and director Ajit Shah. Operating status remains active per the 2024 SEC filing, but there are no public disclosures of clinical milestones, partnerships, or geographic expansion, leaving the company's near-term trajectory dependent on continued capital formation and undisclosed development progress.

Short descriptiontext

Omniox is a San Francisco-based, venture-backed biopharmaceutical company developing an engineered oxygen-carrier platform intended to selectively oxygenate hypoxic tissues in cancer, cardiovascular disease, and trauma. The company is pre-commercial with no products on market and only 1-10 employees.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
engineered oxygen carriers, oxygen delivery therapeutics, hypoxic disease treatment, biopharmaceutical platform, tissue oxygenation technology
Industry1 code
PRIMARYHLAHAGAD
Oxygen Therapy Systems (Concentrators, Cylinders, Liquid O2, HFNC)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Respiratory & Sleep Therapy Devices
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Biopharmaceuticals — Oxygen-Delivery Therapeutics
Social media profiles2 records
Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Omniox develops an engineered oxygen carrier platform technology designed to deliver oxygen specifically to hypoxic tissues. The company targets unmet medical needs in cancer, cardiovascular disease, and trauma by oxygenating tissues where conventional oxygen delivery is insufficient, aiming to overcome treatment resistance associated with tumor and tissue hypoxia. The company is pre-commercial and currently focused on technology development rather than marketed products.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Omniox is an early-stage biopharmaceutical company developing an oxygen-delivery platform technology. The company's engineered oxygen carrier technology is designed to target unmet medical needs related to hypoxic diseases, specifically aiming to improve treatment outcomes for conditions such as cancer and cardiovascular diseases by specifically oxygenating hypoxic tissues. No distinct named products or modules were identified in the available sources.

Product and service1 record
1Oxygen-Delivery Platform Technology
CategoryTherapeutic platform — oxygen-delivery biopharmaceuticals
Description

Engineered oxygen carrier platform designed to selectively deliver oxygen to hypoxic tissues in cancer, cardiovascular disease, and trauma indications, intended for healthcare providers and clinical institutions managing treatment-resistant hypoxic conditions.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers9 records
1Diffusion Pharmaceuticals
TypeDirect peer
Description

Developed trans sodium crocetinate (TSC), a small-molecule oxygen diffusion enhancer targeting hypoxic tumors and stroke. Closely comparable in therapeutic strategy — enhancing oxygen delivery to hypoxic tissues — though delivered via small molecule rather than biologic carrier.

TypeBroad incumbent
Description

Major biologics platform company with significant oncology and cardiovascular franchises. Comparable as a large-scale operator of protein-engineering platforms targeting tissue-level disease mechanisms, and a plausible strategic acquirer profile.

TypeBroad incumbent
Description

Established biologics-focused rare disease company with deep expertise in manufacturing and commercializing biologic therapeutics. Relevant as a benchmark for capital-efficient biologic platform development and a potential strategic acquirer for hypoxia-modulating platforms.

TypeEmerging player
Description

Small-cap immunology platform biotech with protein-engineering expertise targeting inflammatory and oncology indications. Comparable as a similarly-sized, similarly-platform-oriented biotech that advanced to late-stage clinical development and strategic exit.

TypeBroad incumbent
Description

Large-cap biotech with a platform-based approach to serious diseases (CF, sickle cell, pain). Comparable as a successful example of a biotech scaling a mechanistic platform across multiple indications, and a relevant reference for Omniox's trajectory potential.

TypeDirect peer
Description

Clinical-stage biotech developing dodecafluoropentane (DDFPe) emulsion as an oxygen-transport agent for cancer (as a radiosensitizer), stroke, and sickle cell disease. Direct peer targeting the same hypoxia-modulation thesis in oncology and ischemic indications.

TypeDirect peer
Description

Acquired the legacy oxygen-therapeutic assets of Mast Therapeutics, which developed polymerized hemoglobin for sickle cell vaso-occlusive crisis. Direct historical peer in the hemoglobin-based oxygen carrier space targeting similar hypoxic indications.

TypeDirect peer
Description

Developed Sanguinate, a PEGylated bovine hemoglobin-based oxygen carrier for sickle cell disease and other hypoxic conditions. Most directly comparable to Omniox as both pursue hemoglobin/oxygen-carrier biologics for tissue hypoxia, though Prolong has been relatively quiet in recent years.

TypeDirect peer
Description

French biotech developing HEMO2Life, a marine worm (Arenicola marina) hemoglobin-based oxygen carrier for organ preservation and therapeutic oxygen delivery. Direct peer in the oxygen-carrier biologic modality, with applications in ischemia-reperfusion that overlap Omniox's cardiovascular positioning.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Omniox

Biopharmaceuticals — Oxygen-Delivery Therapeuticsomniox.com

Omniox is a San Francisco-based, venture-backed biopharmaceutical company developing an engineered oxygen-carrier platform intended to selectively oxygenate hypoxic tissues in cancer, cardiovascular disease, and trauma. The company is pre-commercial with no products on market and only 1-10 employees.

What Omniox does

Omniox is an early-stage, venture-backed biopharmaceutical company headquartered in San Francisco, California (incorporated in Delaware) that is developing an engineered oxygen-carrier platform designed to deliver oxygen specifically to hypoxic tissues. The company's stated therapeutic thesis targets unmet medical needs in cancer, cardiovascular disease, and trauma, where tissue hypoxia contributes to treatment resistance and poor clinical outcomes; the platform is positioned to selectively oxygenate hypoxic tumors and ischemic cardiovascular tissue rather than functioning as a general blood substitute. Technology disclosure is limited to a high-level description of the oxygen-delivery architecture, with no named product candidates, no disclosed patents, no clinical trial data, and no regulatory milestones provided in available sources.

Omniox operates as a private, R&D-only organization with 1-10 employees, no commercial revenue, and no pricing or distribution model yet established. Its business model to date has been capital-formation-driven: cumulative disclosed equity and debt raises total roughly $28-31 million across rounds dated 2013, 2014 (from Casdin Capital and Wellcome Trust, among others), 2016 (~$28M SEC Form D), 2018, 2023, and 2024 (~$3.36M SEC Form D), with named institutional backers including Casdin Capital, Wellcome Trust, Samsara BioCapital, Acadia Woods Partners, Baker Brothers Advisors, EcoR1 Capital, Wavemaker 360, and Plug and Play. The intended end-customers are healthcare providers and patients in oncology and cardiovascular indications, but the company remains pre-commercial with no active distribution or marketing channels.

Governance is led by CEO Jonathan Winger, with founder Stephen Cary and director Ajit Shah. Operating status remains active per the 2024 SEC filing, but there are no public disclosures of clinical milestones, partnerships, or geographic expansion, leaving the company's near-term trajectory dependent on continued capital formation and undisclosed development progress.

Omniox firmographics

Firmographics
Name
Omniox
Legal name
Omniox, Inc.
Website
https://omniox.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
1–10 employees
Short description
Omniox is a San Francisco-based, venture-backed biopharmaceutical company developing an engineered oxygen-carrier platform intended to selectively oxygenate hypoxic tissues in cancer, cardiovascular disease, and trauma. The company is pre-commercial with no products on market and only 1-10 employees.
Ownership category
akta.pro rank

Omniox industry classification

Industry
Product category
Biopharmaceuticals — Oxygen-Delivery Therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAHAGAD
Oxygen Therapy Systems (Concentrators, Cylinders, Liquid O2, HFNC)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Respiratory & Sleep Therapy Devices

Keywords

  • Engineered oxygen carriers
  • Oxygen delivery therapeutics
  • Hypoxic disease treatment
  • Biopharmaceutical platform
  • Tissue oxygenation technology

Where Omniox is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Omniox business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Omniox product offering

Product offering

Core offering

Omniox develops an engineered oxygen carrier platform technology designed to deliver oxygen specifically to hypoxic tissues. The company targets unmet medical needs in cancer, cardiovascular disease, and trauma by oxygenating tissues where conventional oxygen delivery is insufficient, aiming to overcome treatment resistance associated with tumor and tissue hypoxia. The company is pre-commercial and currently focused on technology development rather than marketed products.

Product overview

Omniox is an early-stage biopharmaceutical company developing an oxygen-delivery platform technology. The company's engineered oxygen carrier technology is designed to target unmet medical needs related to hypoxic diseases, specifically aiming to improve treatment outcomes for conditions such as cancer and cardiovascular diseases by specifically oxygenating hypoxic tissues. No distinct named products or modules were identified in the available sources.

Differentiator

Problem solved

Functional benefit

Products and services

  • Oxygen-Delivery Platform Technology Engineered oxygen carrier platform designed to selectively deliver oxygen to hypoxic tissues in cancer, cardiovascular disease, and trauma indications, intended for healthcare providers and clinical institutions managing treatment-resistant hypoxic conditions.

Companies that use Omniox

Customer profile

Segments1 record

Ideal customer profiles1 record

Omniox technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Omniox partnerships and signals

Strategic signal

Scale indicators2 records

Recent moves3 records

Expansion highlights4 records

Omniox competitors and assessment

Company assessment

Direct peers

  • Diffusion Pharmaceuticals: Developed trans sodium crocetinate (TSC), a small-molecule oxygen diffusion enhancer targeting hypoxic tumors and stroke. Closely comparable in therapeutic strategy — enhancing oxygen delivery to hypoxic tissues — though delivered via small molecule rather than biologic carrier.
  • NuvOx Pharma: Clinical-stage biotech developing dodecafluoropentane (DDFPe) emulsion as an oxygen-transport agent for cancer (as a radiosensitizer), stroke, and sickle cell disease. Direct peer targeting the same hypoxia-modulation thesis in oncology and ischemic indications.
  • Savara Inc. Acquired the legacy oxygen-therapeutic assets of Mast Therapeutics, which developed polymerized hemoglobin for sickle cell vaso-occlusive crisis. Direct historical peer in the hemoglobin-based oxygen carrier space targeting similar hypoxic indications.
  • Prolong Pharmaceuticals: Developed Sanguinate, a PEGylated bovine hemoglobin-based oxygen carrier for sickle cell disease and other hypoxic conditions. Most directly comparable to Omniox as both pursue hemoglobin/oxygen-carrier biologics for tissue hypoxia, though Prolong has been relatively quiet in recent years.
  • Hemarina: French biotech developing HEMO2Life, a marine worm (Arenicola marina) hemoglobin-based oxygen carrier for organ preservation and therapeutic oxygen delivery. Direct peer in the oxygen-carrier biologic modality, with applications in ischemia-reperfusion that overlap Omniox's cardiovascular positioning.

Broad incumbents

  • Regeneron Pharmaceuticals: Major biologics platform company with significant oncology and cardiovascular franchises. Comparable as a large-scale operator of protein-engineering platforms targeting tissue-level disease mechanisms, and a plausible strategic acquirer profile.
  • BioMarin Pharmaceutical: Established biologics-focused rare disease company with deep expertise in manufacturing and commercializing biologic therapeutics. Relevant as a benchmark for capital-efficient biologic platform development and a potential strategic acquirer for hypoxia-modulating platforms.
  • Vertex Pharmaceuticals: Large-cap biotech with a platform-based approach to serious diseases (CF, sickle cell, pain). Comparable as a successful example of a biotech scaling a mechanistic platform across multiple indications, and a relevant reference for Omniox's trajectory potential.

Emerging players

  • Alpine Immune Sciences: Small-cap immunology platform biotech with protein-engineering expertise targeting inflammatory and oncology indications. Comparable as a similarly-sized, similarly-platform-oriented biotech that advanced to late-stage clinical development and strategic exit.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Omniox social profiles

Digital presence

Omniox financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Omniox leadership team

Management profile

Number of profiles

Profiles3 records

Omniox funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Omniox M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Omniox

What does Omniox do?

Omniox develops an engineered oxygen carrier platform technology designed to deliver oxygen specifically to hypoxic tissues. The company targets unmet medical needs in cancer, cardiovascular disease, and trauma by oxygenating tissues where conventional oxygen delivery is insufficient, aiming to overcome treatment resistance associated with tumor and tissue hypoxia. The company is pre-commercial and currently focused on technology development rather than marketed products.

Is Omniox a public or private company?

Omniox is a private company. It is classified as venture growth investor backed and is currently operating.

When was Omniox founded?

Omniox was founded in 2016. It employs 1 to 10 people.

Where is Omniox based?

Omniox is headquartered in San Francisco, United States, in the North America region.

Who are Omniox's main competitors?

Direct peers on record are Diffusion Pharmaceuticals, NuvOx Pharma, Savara Inc., Prolong Pharmaceuticals and Hemarina. Broad incumbents are Regeneron Pharmaceuticals, BioMarin Pharmaceutical and Vertex Pharmaceuticals. Alpine Immune Sciences is listed as an emerging player.

Does Omniox have an API?

No public API is recorded for Omniox.

What industry is Omniox in?

Omniox's product category is Biopharmaceuticals — Oxygen-Delivery Therapeutics. Its primary akta.pro industry code is HLAHAGAD, Oxygen Therapy Systems (Concentrators, Cylinders, Liquid O2, HFNC). Its NAICS code is 325414 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals